| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Elaine Hylek | Q43198009 |
| P2093 | author name string | Henry I Bussey | |
| Ann K Wittkowsky | |||
| Marie B Walker | |||
| P2860 | cites work | A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data | Q31004538 |
| Association of warfarin dose with genes involved in its action and metabolism | Q35633802 | ||
| Genetic-based dosing in orthopedic patients beginning warfarin therapy. | Q35989429 | ||
| The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen | Q46537717 | ||
| Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. | Q53257773 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 141-143 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Genetic testing for warfarin dosing? Not yet ready for prime time | |
| P478 | volume | 28 |
| Q37031513 | Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy |
| Q33832923 | Debating clinical utility |
| Q33410725 | Estimation of the warfarin dose with clinical and pharmacogenetic data |
| Q35900767 | Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study |
| Q35218128 | Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design |
| Q43114229 | Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response |
| Q33550741 | Integration of genetic, clinical, and INR data to refine warfarin dosing |
| Q37867275 | Patient factors that influence warfarin dose response |
| Q37461474 | Pharmacogenetics of vitamin K antagonists: useful or hype? |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q34965532 | Pharmacogenetics: from discovery to patient care |
| Q57179825 | Pharmacogenomics Aspect of Warfarin Therapy |
| Q37367170 | Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery |
| Q37169126 | Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy |
| Q33561482 | Warfarin pharmacogenomics |
Search more.